Indeed, using the “matrisome” approach developed by R. Hynes and A. Naba (http://matrisomeproject.mit.edu), we show that pharmacologic FAK inhibition in primary CAFs isolated from patient tumours globally decreases the expression of ECM proteins from the “core matrisome” (collagens, glycoproteins and proteoglycans) and ECM regulators. This evidence concerns the gene PTK2 and neoplasm.